Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:57:50 EDT Tue 29 Apr 2025
Enter Symbol
or Name
USA
CA



Q:CORT - CORCEPT THERAPEUTICS INC - https://www.corcept.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CORT - Q2.072.00·75.000.673.23+2.283.2816.958,63813,20071.66  73.57  70.08117.33  22.6019:55:17Apr 2815 min RT 2¢

Recent Trades - Last 10 of 13200
Time ETExPriceChangeVolume
19:55:17Q71.780.8325
18:44:54Q74.703.756
18:23:56Q74.663.71100
17:42:23Q74.74993.79991
17:38:24Q73.232.282
17:21:47Q74.67583.725810
17:21:25Q74.743.792
17:09:20Q74.753.802
17:06:24Q73.232.2826,258
16:54:52Q74.74993.79991

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-04-28 16:05U:CORTNews ReleaseCORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL
2025-04-23 11:30U:CORTNews ReleaseCORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
2025-04-21 08:00U:CORTNews ReleaseDiabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
2025-04-07 08:00U:CORTNews ReleaseCorcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
2025-03-31 08:00U:CORTNews ReleasePrimary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
2025-03-10 08:00U:CORTNews ReleaseCorcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
2025-03-03 16:05U:CORTNews ReleaseFDA Files Corcept's New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
2025-02-26 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
2025-02-12 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
2024-12-30 17:15U:CORTNews ReleaseCorcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
2024-12-16 08:00U:CORTNews ReleaseCorcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
2024-12-12 16:05U:CORTNews ReleaseCorcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes
2024-12-11 16:05U:CORTNews ReleaseCorcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
2024-10-30 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update
2024-10-23 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
2024-07-29 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
2024-07-22 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
2024-06-24 16:15U:CORTNews ReleaseCorcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions
2024-06-03 08:00U:CORTNews ReleaseCorcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome)
2024-05-28 08:00U:CORTNews ReleaseCorcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing's Syndrome)